TRANSCENTA-B (06628) announced that its partner, Inhibrx Biosciences (NASDAQ: INBX), has released positive primary results from the registrational clinical study ChonDRAgon (n=206). The study evaluated the efficacy of ozekibart (INBRX-109) as a monotherapy compared to placebo in patients with advanced or metastatic, unresectable chondrosarcoma. Based on these results, Inhibrx plans to submit a Biologics License Application (BLA) for ozekibart in chondrosarcoma to U.S. regulators by the end of June 2026.

Under a licensing agreement through its wholly-owned subsidiary Hangzhou Just Biotherapeutics (HJB), TRANSCENTA-B holds exclusive development and commercialization rights for ozekibart in mainland China, Hong Kong SAR, Macau SAR, and Taiwan.

Ozekibart is the first investigational drug to demonstrate significant improvement in progression-free survival (PFS) for chondrosarcoma patients in a randomized controlled trial. Currently, there are no approved systemic treatments for this condition. The encouraging clinical data further validates the drug's potential value for global patients, particularly in regions where TRANSCENTA-B holds exclusive rights.

Beyond the registrational trial, Inhibrx is advancing an expansion cohort to evaluate ozekibart in combination with irinotecan-based regimens for Ewing sarcoma and colorectal cancer. Early results show promising signals, supporting further exploration of ozekibart's potential in these high-need, refractory cancers.